Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E/C/F/TAF in HIV-1 Infected Virologically Suppressed Adolescents
NCT02276612Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Dec 2014
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of tenofovir alafenamide in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Gilead Sciences. Primary endpoints: Incidence of Treatment-Emergent Serious Adverse Events at Week 48 and Incidence of Treatment-Emergent Adverse Events at Week 48. Started Dec 2014; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02276612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02276612.